PRRT2 and B-cell non-Hodgkin lymphoma: The net result is a significant reduction in tumor cell growth, cell proliferation, and induction of apoptosis, thereby indicating the potential of PKC-inhibitors such as enzastaurin in the treatment of B-cell lymphomas.